Assessing the safety and pharmacokinetics of the anti-HIV monoclonal antibody CAP256V2LS alone and in combination with VRC07-523LS and PGT121 in South African women: study protocol for the first-in-human CAPRISA 012B phase I clinical trial.
Sharana MahomedQuarraisha A KarimNonhlanhla Y ZumaEdmund CapparelliCheryl BaxterTanuja GengiahDerseree ArcharyNatasha SamsunderNicole D RosePenny MooreCarolyn WilliamsonDan H BarouchPatricia E FastBruno PozzettoCatherine HankinsKevin CarltonJulie LedgerwoodLynn MorrisJohn MascolaSalim Abdool KarimPublished in: BMJ open (2020)
PACTR202003767867253; Pre-results.
Keyphrases
- monoclonal antibody
- clinical trial
- endothelial cells
- antiretroviral therapy
- hiv positive
- hiv infected
- human immunodeficiency virus
- polycystic ovary syndrome
- hiv testing
- hepatitis c virus
- induced pluripotent stem cells
- hiv aids
- pluripotent stem cells
- open label
- phase ii
- type diabetes
- randomized controlled trial
- study protocol
- double blind
- pregnant women
- metabolic syndrome
- south africa
- insulin resistance
- skeletal muscle
- cervical cancer screening